536 related articles for article (PubMed ID: 9506248)
1. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
Bartow RA; Brogden RN
Drugs; 1998 Feb; 55(2):303-22. PubMed ID: 9506248
[TBL] [Abstract][Full Text] [Related]
2. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Faulds D; Hollingshead LM; Goa KL
Drugs; 1991 Jul; 42(1):115-37. PubMed ID: 1718682
[TBL] [Abstract][Full Text] [Related]
3. The use of inhaled formoterol in the treatment of asthma.
Berger WE
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777
[TBL] [Abstract][Full Text] [Related]
4. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma.
Welsh EJ; Cates CJ
Cochrane Database Syst Rev; 2010 Sep; 2010(9):CD008418. PubMed ID: 20824877
[TBL] [Abstract][Full Text] [Related]
5. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
[TBL] [Abstract][Full Text] [Related]
6. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
Holimon TD; Chafin CC; Self TH
Drugs; 2001; 61(3):391-418. PubMed ID: 11293649
[TBL] [Abstract][Full Text] [Related]
7. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
Sovani MP; Whale CI; Tattersfield AE
Drug Saf; 2004; 27(10):689-715. PubMed ID: 15350154
[TBL] [Abstract][Full Text] [Related]
8. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
Bisgaard H
Pediatr Pulmonol; 2000 Mar; 29(3):221-34. PubMed ID: 10686044
[TBL] [Abstract][Full Text] [Related]
9. Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration.
Löfdahl CG; Svedmyr N
Allergy; 1989 May; 44(4):264-71. PubMed ID: 2544117
[TBL] [Abstract][Full Text] [Related]
10. Inhaled long acting beta agonists for stable chronic asthma.
Walters EH; Walters JA; Gibson MD
Cochrane Database Syst Rev; 2003; (4):CD001385. PubMed ID: 14583933
[TBL] [Abstract][Full Text] [Related]
11. From adrenaline to formoterol: advances in beta-agonist therapy in the treatment of asthma.
Campbell LM
Int J Clin Pract; 2002 Dec; 56(10):783-90. PubMed ID: 12510953
[TBL] [Abstract][Full Text] [Related]
12. Formoterol: a review of its use in chronic obstructive pulmonary disease.
Cheer SM; Scott LJ
Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
[TBL] [Abstract][Full Text] [Related]
13. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.
Walters EH; Walters JA; Gibson PW
Cochrane Database Syst Rev; 2002; 2002(4):CD003901. PubMed ID: 12519616
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma.
McKeage K
Drugs; 2013 Feb; 73(2):195-206. PubMed ID: 23397367
[TBL] [Abstract][Full Text] [Related]
15. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?
Lipworth BJ
Drug Saf; 1997 May; 16(5):295-308. PubMed ID: 9187530
[TBL] [Abstract][Full Text] [Related]
16. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
[TBL] [Abstract][Full Text] [Related]
17. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
Grove A; Lipworth BJ
Thorax; 1996 Jun; 51(6):585-9. PubMed ID: 8693438
[TBL] [Abstract][Full Text] [Related]
18. Long-acting inhaled beta2-agonists in asthma therapy.
Moore RH; Khan A; Dickey BF
Chest; 1998 Apr; 113(4):1095-108. PubMed ID: 9554653
[TBL] [Abstract][Full Text] [Related]
19. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
20. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
